TD-0903 - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.27 [0.03, 2.26]< 10%2 studies (2/-)88.4 %some concernnot evaluable moderatecrucial-
deaths 0.27 [0.03, 2.26]< 10%2 studies (2/-)88.4 %some concernnot evaluable moderatecrucial-
clinical improvement 2.74 [0.40, 18.83]> 10%2 studies (2/-)84.6 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 2.74 [0.40, 18.83]> 10%2 studies (2/-)84.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.08 [0.01, 0.86]< 10%2 studies (2/-)98.1 %some concernnot evaluable moderateimportant-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
adverse events 0.12 [0.01, 1.37]< 12%2 studies (2/-)95.5 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.